Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, remains under FDA review. The update provides no approval decision or new timing, leaving the program's near-term regulatory outlook uncertain.